Document Detail


Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
MedLine Citation:
PMID:  16510746     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated patients.
METHODS: We invited patients who had participated in clinical trials in which they received recent or long-term treatment with natalizumab for multiple sclerosis, Crohn's disease, or rheumatoid arthritis to participate. The clinical history, physical examination, brain magnetic resonance imaging (MRI), and testing of cerebrospinal fluid for JC virus DNA were used by an expert panel to evaluate patients for PML. We estimated the risk of PML in patients who completed at least a clinical examination for PML or had an MRI.
RESULTS: Of 3417 patients who had recently received natalizumab while participating in clinical trials, 3116 (91 percent) who were exposed to a mean of 17.9 monthly doses underwent evaluation for PML. Of these, 44 patients were referred to the expert panel because of clinical findings of possible PML, abnormalities on MRI, or a high plasma viral load of JC virus. No patient had detectable JC virus DNA in the cerebrospinal fluid. PML was ruled out in 43 of the 44 patients, but it could not be ruled out in one patient who had multiple sclerosis and progression of neurologic disease because data on cerebrospinal fluid testing and follow-up MRI were not available. Only the three previously reported cases of PML were confirmed (1.0 per 1000 treated patients; 95 percent confidence interval, 0.2 to 2.8 per 1000).
CONCLUSIONS: A detailed review of possible cases of PML in patients exposed to natalizumab found no new cases and suggested a risk of PML of roughly 1 in 1000 patients treated with natalizumab for a mean of 17.9 months. The risk associated with longer treatment is not known.
Authors:
Tarek A Yousry; Eugene O Major; Caroline Ryschkewitsch; Gary Fahle; Steven Fischer; Jean Hou; Blanche Curfman; Katherine Miszkiel; Nicole Mueller-Lenke; Esther Sanchez; Frederik Barkhof; Ernst-Wilhelm Radue; Hans R Jäger; David B Clifford
Related Documents :
2027486 - Relapsing transverse myelitis.
2583936 - Cognitive function in multiple sclerosis and its relation to functional abilities.
16403156 - Programmable multiple pacing configurations help to overcome high left ventricular paci...
15626476 - Evolution of self-reactive igg antibody repertoires in patients with relapsing-remittin...
25221586 - Changes in motor function in the unaffected hand of stroke patients should not be ignored.
778456 - Intravenous fructose for acute alcoholism: a double blind study.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural    
Journal Detail:
Title:  The New England journal of medicine     Volume:  354     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-03-02     Completed Date:  2006-03-07     Revised Date:  2011-11-04    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  924-33     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2006 Massachusetts Medical Society.
Affiliation:
Institute of Neurology, Queen Square, London.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects*,  therapeutic use
Arthritis, Rheumatoid / drug therapy
Clinical Trials as Topic
Crohn Disease / drug therapy
DNA, Viral / cerebrospinal fluid
Humans
JC Virus / genetics,  isolation & purification*
Leukoencephalopathy, Progressive Multifocal / chemically induced*,  diagnosis
Magnetic Resonance Imaging
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Risk
Grant Support
ID/Acronym/Agency:
748//Multiple Sclerosis Society
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/DNA, Viral; 0/natalizumab
Comments/Corrections
Comment In:
N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9   [PMID:  16742008 ]
N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9   [PMID:  16738278 ]
N Engl J Med. 2006 Mar 2;354(9):965-7   [PMID:  16510751 ]
N Engl J Med. 2006 Jun 1;354(22):2387-9; author reply 2387-9   [PMID:  16742009 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Next Document:  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.